Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2016-10-11, 09:16:46 | version 1.38.0
04 Dental Tribune Asia Pacific Edition | 7+8/2016 WORLD NEWS Henry Schein completes Asia investment By DTI KYOTO, Japan/MELVILLE, USA: Last week, Henry Schein announced the completion of a 50 per cent equity investment in One Piece Corpo- ration, a subsidiary of J. Morita. Henry Schein first entered the Japanese market in October 2014, with an investment in Iwase Den- tal Supply, a full-service provider of dental consumables, implants and equipment. “We are delighted to move for- ward with our partnership with Henry Schein,” said Haruo Morita, President and CEO of J. Morita. “We share a devotion to innovation, the ability to adapt to changing market conditions, and a strong commitment to industry leader- ship that will enhance our efforts to help practicing dentists in Japan deliver quality oral health care.” With the partnership, Henry Schein has expanded its presence in Japan, the second-largest dental market in the world. One Piece is composed of eight dental dealers throughout Japan, which serve approximately 6,000 dental clin- ics and had aggregate sales of approximately US$125 million in the 2015 fiscal year. Commenting on the partner- ship, Henry Schein CEO Stanley M. Bergman said: “We are committed to the Japan dental market and with Kenichiro Iwase, assuming the leadership of Henry Schein Japan, we look forward to a strong partnership that will bring new services and solutions to the Japanese dental community.” Japan has approximately 90,000dentistsandabout64,000 dental clinics. With the addition of One Piece, Henry Schein Japan will serve approximately 20 per cent of Japan’s dentists. By DTI SINGAPORE: In order to help clin- icians to create lifelike direct resin restorations, dental materials company SHOFU has introduced Beautifil II Enamel and Gingiva. Developed as complementary ex- tensions to Beautifil II, both are made from specially modified multifunctional organic fillers and nano-fillers, providing them with exceptional handling char- acteristics, longer working time, high abrasion and wear resistance, as well as stable shades, the com- pany said. Moreover, effortless and supe- rior polishing with sustained polish retention achieves lasting aesthetics. SHOFU’s proprietary S-PRG fillers release fluoride and exert an anti- plaque effect on the restoration sur- face. A special one-push syringe en- sures controlled dispensing of the smooth and creamy material that is easy to sculpt into fine details to recreate the surface textures seen in natural teeth and gingivae. Beautifil II Enamel is available in four naturally translucent and opalescent shades that facilitate lifelike shade reproduction and value adjustment in the final restoration to meet individual clinical needs. Beautifil II Gingiva offers five natural shade varia- tions of pink to easily mimic the patient’s gingivae while re- storing areas with receded or missing gingivae or papillae, cervical defects, root caries or ero- sion, or exposed porcelain-fused- to-metal margins and abutments to achieve red and white aesthetic harmony. DenTech 2016 26.–29.10.2016 German Pavillion Dental Material GmbH 24537 Neumünster / Germany Tel. +49 43 21 / 5 41 73 Fax +49 43 21 / 5 19 08 eMail info@promedica.de Internet www.promedica.de Visit www.promedica.de to see all our products Light-curing radiopaque calcium hydroxide • High compressive strength • Excellent adhesion, especially to composites • Effective pulp protection • Acid resistant • radiopaque Temporary crown & bridge material • less than 5 min. processing time • strong functional load • perfect long-term aesthetics • excellent biocompatibility Glass Ionomer Filling Cement • For fillings of classe I, III and IV • Excellent biocompatibility and low acidity • High compressive strength • No temperature rise during setting • Enamel-like translucency • Excellent radiopacity • Stable and abrasion resistant AD Red and white aesthetic harmony Straumann: Controlling stake in MegaGen By DTI BASEL, Switzerland: Straumann has announced that is exercising its conversion right and call op- tion to acquire a controlling stake in South Korean implant man- ufacturer MegaGen. The option was obtained in March 2014, when Straumann agreed to purchase convertible bonds from MegaGen for a total of US$30 million (€27 billion). The bond agreements be- tween the two companies provide Straumann with the right to con- vert them into MegaGen shares. An additional agreement with the main shareholders of MegaGen entitles Straumann to purchase an additional number of shares in MegaGen to obtain a controlling stake in MegaGen. Straumann’s decision to exer- cise the conversion right and call option has triggered the process in the agreements to determine the conversion rate and the price of the additional shares. MegaGen has disputed the conversion price and calculation procedure and has initiated arbitration in Seoul in South Korea under the Inter- national Chamber of Commerce rules. Expediency is in the best interests of all parties involved, and Straumann is in the process of responding in order to close the deal as soon as possible. This could take up to two years, de- pending on the progress of the arbitration. Straumann CEO Marco Gadola explained: “Our investment has helped MegaGen to drive its growth strategy and to achieve good results in 2015. However, with its domestic market highly penetrated and our industry con- solidating rapidly, we are firmly convinced that it is in the best interest of MegaGen’s employees, customers and shareholders to have a strong global partner who can help the company to provide complete solutions and to expand internationally. At the same time, MegaGen complements our port- folio with differentiated products and could help us to address the value segment more effectively particularly in the Asia-Pacific and Middle East regions.” Tel. +494321 / 54173 Fax +494321 / 51908